Takeeda Masanori, Yamato Masanori, Kato Shinichi, Takeuchi Koji
Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto 607-8414, Japan.
J Pharmacol Exp Ther. 2003 Nov;307(2):713-9. doi: 10.1124/jpet.103.054973. Epub 2003 Sep 15.
We investigated the preferential role of cyclooxygenase (COX) isozymes in various functional changes of the rat stomach after exposure to taurocholate (TC) as a mild irritant. Under urethane anesthesia, a rat stomach mounted in an ex vivo chamber was perfused with saline or acid (50 mM HCl), and transmucosal potential difference (PD), gastric mucosal blood flow (GMBF), and acid secretion were measured before and after exposure of the stomach to 20 mM TC for 30 min. Indomethacin, 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole (SC-560) (a selective COX-1 inhibitor), or rofecoxib (a selective COX-2 inhibitor) was given intraduodenally 30 min before the TC treatment. Mucosal application of TC caused a marked reduction in PD, followed by a decrease of acid secretion and an increase of GMBF. Previous administration of indomethacin did not affect the reduction in PD but significantly mitigated the two other responses induced by TC, resulting in a delay in the recovery in PD. These effects were mimicked by SC-560 but not rofecoxib, although neither of these drugs had any effect on the reduction in PD. Perfusion of TC-treated stomachs with 50 mM HCl caused only minimal damage, yet this treatment produced gross lesions in the presence of indomethacin or SC-560. Mucosal exposure to TC increased prostaglandin E2 production, but the response was inhibited by both indomethacin and SC-560 but not rofecoxib. These results suggested that COX-1 but not COX-2 is a key enzyme for regulating the functional alterations of the stomach and for maintaining the mucosal integrity after barrier disruption.
我们研究了环氧化酶(COX)同工酶在大鼠胃暴露于牛磺胆酸盐(TC)作为轻度刺激物后各种功能变化中的优先作用。在乌拉坦麻醉下,将置于离体腔室中的大鼠胃用生理盐水或酸(50 mM HCl)灌注,并在胃暴露于20 mM TC 30分钟前后测量跨粘膜电位差(PD)、胃粘膜血流量(GMBF)和酸分泌。在TC处理前30分钟十二指肠内给予吲哚美辛、5-(4-氯苯基)-1-(4-甲氧基苯基)-3-三氟甲基吡唑(SC-560)(一种选择性COX-1抑制剂)或罗非昔布(一种选择性COX-2抑制剂)。粘膜应用TC导致PD显著降低,随后酸分泌减少,GMBF增加。预先给予吲哚美辛并不影响PD的降低,但显著减轻了TC诱导的其他两种反应,导致PD恢复延迟。这些作用被SC-560模拟,但未被罗非昔布模拟,尽管这两种药物对PD的降低均无任何影响。用50 mM HCl灌注经TC处理的胃仅造成最小程度的损伤,但在存在吲哚美辛或SC-560的情况下,这种处理会产生严重病变。粘膜暴露于TC会增加前列腺素E2的产生,但该反应被吲哚美辛和SC-560均抑制,而未被罗非昔布抑制。这些结果表明,COX-1而非COX-2是调节胃功能改变和维持屏障破坏后粘膜完整性的关键酶。